Jennifer A Wargo

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Surgical management of melanoma
    Jennifer A Wargo
    Department of Surgery, Harvard Medical School, Boston, MA, USA
    Hematol Oncol Clin North Am 23:565-81, x. 2009
  2. pmc Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer
    Viswanath Gunda
    Massachusetts General Hospital, Harvard Medical School, Boston, MA
    Surgery 154:1456-62; discussion 1462. 2013
  3. pmc BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
    Dennie T Frederick
    Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 19:1225-31. 2013
  4. pmc N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma
    Nakul P Valsangkar
    Department of Surgery and Andrew L Warshaw, M D, Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Gastrointest Surg 17:257-66. 2013
  5. pmc TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
    Ryan B Corcoran
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 5:196ra98. 2013
  6. pmc MITF Modulates Therapeutic Resistance through EGFR Signaling
    Zhenyu Ji
    Wellman Center for Photomedicine Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Invest Dermatol 135:1863-72. 2015
  7. pmc A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
    Cory M Johannessen
    1 The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA 2 Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA 3 Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 02115, USA
    Nature 504:138-42. 2013
  8. pmc Elucidating distinct roles for NF1 in melanomagenesis
    Ophélia Maertens
    Genetics Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02115, USA
    Cancer Discov 3:338-49. 2013
  9. pmc Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF
    Rizwan Haq
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Cancer Cell 23:302-15. 2013
  10. pmc FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience
    Jason E Faris
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 18:543-8. 2013

Collaborators

Detail Information

Publications23

  1. doi request reprint Surgical management of melanoma
    Jennifer A Wargo
    Department of Surgery, Harvard Medical School, Boston, MA, USA
    Hematol Oncol Clin North Am 23:565-81, x. 2009
    ....
  2. pmc Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer
    Viswanath Gunda
    Massachusetts General Hospital, Harvard Medical School, Boston, MA
    Surgery 154:1456-62; discussion 1462. 2013
    ..Baseline expression levels of the MAGE-A4 gene in thyroid cancer cell lines have not been previously studied thoroughly...
  3. pmc BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
    Dennie T Frederick
    Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 19:1225-31. 2013
    ..To evaluate the effects of BRAF inhibition on the tumor microenvironment in patients with metastatic melanoma...
  4. pmc N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma
    Nakul P Valsangkar
    Department of Surgery and Andrew L Warshaw, M D, Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Gastrointest Surg 17:257-66. 2013
    ..We evaluated the prognostic accuracy of LN variables (N0/N1), numbers of positive lymph nodes (PLN), and lymph node ratio (LNR) in the context of the total number of examined lymph nodes (ELN)...
  5. pmc TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
    Ryan B Corcoran
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 5:196ra98. 2013
    ..Such a change in P-S6 could be readily monitored in real time by serial fine-needle aspiration biopsies, making quantitation of P-S6 a valuable biomarker to guide treatment in BRAF-mutant melanoma. ..
  6. pmc MITF Modulates Therapeutic Resistance through EGFR Signaling
    Zhenyu Ji
    Wellman Center for Photomedicine Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Invest Dermatol 135:1863-72. 2015
    ..This resistance loop modulates drug response and could explain the unique sensitivity of melanomas to BRAF inhibition. ..
  7. pmc A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
    Cory M Johannessen
    1 The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA 2 Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA 3 Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 02115, USA
    Nature 504:138-42. 2013
    ..Collectively, these data suggest that oncogenic dysregulation of a melanocyte lineage dependency can cause resistance to RAF-MEK-ERK inhibition, which may be overcome by combining signalling- and chromatin-directed therapeutics. ..
  8. pmc Elucidating distinct roles for NF1 in melanomagenesis
    Ophélia Maertens
    Genetics Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02115, USA
    Cancer Discov 3:338-49. 2013
    ..Collectively, these studies provide mechanistic insight into how NF1 cooperates with BRAF mutations in melanoma and show that NF1/neurofibromin inactivation may have an impact on responses to targeted therapies...
  9. pmc Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF
    Rizwan Haq
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Cancer Cell 23:302-15. 2013
    ..Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxidative phosphorylation. Our data thus identify an adaptive metabolic program that limits the efficacy of BRAF inhibitors...
  10. pmc FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience
    Jason E Faris
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 18:543-8. 2013
    ..However, the recurrences following R0 resection in three of five patients and the toxicities observed with the use of this regimen raise important questions about how to best treat patients with LAPC...
  11. pmc Evolution of the Whipple procedure at the Massachusetts General Hospital
    Carlos Fernandez-del Castillo
    Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Surgery 152:S56-63. 2012
    ..The goal of this study was to investigate the evolution of pancreatoduodenectomy at the Massachusetts General Hospital (MGH)...
  12. doi request reprint Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital
    Zhi Ven Fong
    Department of Surgery, Massachusetts General Hospital, 15 Parkman Street, Boston, 02114 3117, MA, USA
    J Gastrointest Surg 18:137-44; discussion 144-5. 2014
    ..We sought to delineate the natural history and predictive factors of readmissions after PD...
  13. pmc A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression
    Viswanath Gunda
    1 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    Thyroid 24:1241-50. 2014
    ..This cytoplasmic antigen can serve as a potent target for cancer immunotherapy and yet has not been well studied in differentiated thyroid cancer cells...
  14. doi request reprint Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
    Ioannis T Konstantinidis
    Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Ann Surg 257:731-6. 2013
    ..Our aim was to compare the survival of patients undergoing an R1 resection with those having LA tumors and to explore the prognostic significance of a 1-mm surgical margin...
  15. pmc 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital
    Nakul P Valsangkar
    General and GI Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Surgery 152:S4-12. 2012
    ..The objective of this study was to identify trends in the diagnosis and treatment of cystic neoplasms of the pancreas using a retrospective review of patients from a surgical database at an academic referral center during a 33-year period...
  16. pmc Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
    Adam A Friedman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States of America Dermatology and Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America
    PLoS ONE 10:e0140310. 2015
    ..Thus, high-throughput unbiased screening of targeted drug combinations, with appropriate library selection and mechanistic follow-up, can yield clinically-actionable drug combinations. ..
  17. pmc EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma
    Benchun Miao
    Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts Department of Dermatology, Harvard Medical School, Boston, Massachusetts
    Cancer Discov 5:274-87. 2015
    ..These results provide proof of concept that RTK-guided growth, and therapeutic resistance, can be prospectively defined and selectively targeted...
  18. pmc Targeting the MAGE A3 antigen in pancreatic cancer
    Alexandria P Cogdill
    Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Surgery 152:S13-8. 2012
    ..The results of these studies have important translational implications and provide the rationale for combined treatment with chromatin remodeling agents and immunotherapeutic approaches for pancreatic cancer...
  19. doi request reprint Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood
    Michael S Gee
    Department of Radiology, Massachusetts General Hospital, Boston, MA Center for Systems Biology, Massachusetts General Hospital, Boston, MA Electronic address
    Nanomedicine . 2016
    ..These results indicate μNMR technology provides minimally invasive point-of-care evaluation of tumor signaling and metastatic burden in melanoma patients...
  20. pmc PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
    Francesco Sabbatino
    Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA
    Oncotarget 5:1926-41. 2014
    ....
  21. pmc BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
    Rizwan Haq
    Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:4321-6. 2013
    ..These studies identify MITF-BCL2A1 as a lineage-specific oncogenic pathway in melanoma and underscore its role for improved response to BRAF-directed therapy...
  22. pmc EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    Ryan B Corcoran
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Cancer Discov 2:227-35. 2012
    ..These findings support evaluation of combined RAF and EGFR inhibition in BRAF mutant CRC patients...
  23. doi request reprint Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
    Andrea Boni
    Division of Surgical Oncology, Medical Oncology, and Dermatology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Res 70:5213-9. 2010
    ..These findings have important implications for combined kinase-targeted therapy plus immunotherapy for melanoma...